<SEC-DOCUMENT>0001104659-25-093161.txt : 20250925
<SEC-HEADER>0001104659-25-093161.hdr.sgml : 20250925
<ACCEPTANCE-DATETIME>20250925090018
ACCESSION NUMBER:		0001104659-25-093161
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20250924
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250925
DATE AS OF CHANGE:		20250925

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HELIUS MEDICAL TECHNOLOGIES, INC.
		CENTRAL INDEX KEY:			0001610853
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				364787690
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38445
		FILM NUMBER:		251340423

	BUSINESS ADDRESS:	
		STREET 1:		642 NEWTOWN YARDLEY ROAD
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
		BUSINESS PHONE:		215-944-6100

	MAIL ADDRESS:	
		STREET 1:		642 NEWTOWN YARDLEY ROAD
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HELIUS MEDICAL TECHNOLOGIES, INC
		DATE OF NAME CHANGE:	20180517

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HELIUS MEDICAL TECHNOLOGIES, INC.
		DATE OF NAME CHANGE:	20140613
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>hsdt-20250924x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.0.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 9/24/2025 9:30:38 PM -->
<!-- iXBRL Library version: 1.0.9292.28120 -->
<!-- iXBRL Service Job ID: 2bf2969b-0749-48f5-bd0c-6bcd1b047453 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:hsdt="http://www.heliusmedical.com/20250924" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:EntityCentralIndexKey" id="Tc_GB-oXb7IDEG7bdEY56k7gw_2_1">0001610853</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:AmendmentFlag" id="Tc_6HQPzYykZUyxS1BX90dAXA_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="hsdt-20250924.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610853</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-24</xbrli:startDate><xbrli:endDate>2025-09-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:51.75pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_122912ca_5062_4451_9d58_72220c5f570b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:DocumentType" id="Narr_BABod1V0w0S6JdVtIuKTxg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_mkjTcQIZFUWd2Z7sJxx_vg"><b style="font-weight:bold;">September 24, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;"><img src="hsdt-20250924x8k001.jpg" alt="Graphic" style="display:inline-block;height:51.75pt;width:111.75pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:EntityRegistrantName" id="Narr_VSVuPOekZkKzyMgTd2V58w"><b style="font-weight:bold;">HELIUS MEDICAL TECHNOLOGIES, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_e26acd34_823b_496a_99cb_0c7acf7355a5"></a><a id="Tc_HlZ-1DFZUECGzis3N4ZuXg_0_0"></a><a id="Tc_7b_NkZGHPkWqi7o3R07wSw_2_0"></a><a id="Tc_GRLN2mj_OkGyg6IIfK8hng_2_1"></a><a id="Tc_kFsA18wOzkylox85aCUqPA_2_2"></a><a id="Tc_U4PLF__Iu0OJl7eSt-ucnQ_4_0"></a><a id="Tc_BXtGZsqB10qIo08A2FZcsw_5_0"></a><a id="Tc_dvm4JFudQUuvf1J93BwiEQ_5_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;">-</p></div></div></td><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:30.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_EbiJOc9j4EibYnRUgUn3Xg_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:EntityFileNumber" id="Tc_nOoD7o1cX0eIxeXM4tBBiA_1_1"><b style="font-weight:bold;">001-38445</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:30.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:EntityTaxIdentificationNumber" id="Tc_ddJzQy76RkyJdNgXi5VGPw_1_2"><b style="font-weight:bold;">36-4787690</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:bottom;width:30.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(IRS Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:EntityAddressAddressLine1" id="Narr_rMwKqncEQ029rA9cB2A4fg"><b style="font-weight:bold;">642 Newtown Yardley Road</b></ix:nonNumeric><b style="font-weight:bold;">,</b><b style="font-weight:bold;">&#160;</b><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:EntityAddressAddressLine2" id="Narr_1eWxY3Z1hUe90Rzg1M7oCg"><b style="font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:EntityAddressCityOrTown" id="Narr_tFewQUpYSUuJ9coulBQ1fQ"><b style="font-weight:bold;">Newtown</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:EntityAddressStateOrProvince" id="Narr_K7AOauMmyUycdetfxL8uSA"><b style="font-weight:bold;">PA</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:30.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:EntityAddressPostalZipCode" id="Tc_fJYV2yo3K0qoPiBnqscbng_4_2"><b style="font-weight:bold;">18940</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:30.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:CityAreaCode" id="Narr_gkgkQ9Vda06q7ARU8wSi_Q"><b style="font-weight:bold;">215</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:LocalPhoneNumber" id="Narr_83vQAl32v0W5I9NNdokAzQ"><b style="font-weight:bold;">944-6100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_61edffe2_937d_4f98_a4f6_6c57bcb51132"></a><a id="Tc_xcNMxOZGNkObP4SaFk9Mxw_1_1"></a><a id="Tc_llYZKMnGDE6w94hs_FdGZw_2_1"></a><a id="Tc_exziYYHfL0mkdSgDgV_dag_3_1"></a><a id="Tc_Lwb4xI6UYUSFDH9-bNv1vQ_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:90.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:9.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_XOGbFb8WaUugQbDK8-Rnew_1_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:90.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr><td style="vertical-align:top;width:9.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_0PsP9epCu0eWsihtncilRA_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:90.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:9.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_gu_VKPNTZUaCXP7KTQURAw_3_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:90.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:9.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_6PjSdbYwqU2Dai-gL1HQOw_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:90.9%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_20ce40c8_b077_4e5f_a4dd_32c783822c74"></a><a id="Tc_6pIdQT4XukiMaIly-K89NA_1_0"></a><a id="Tc_2tGJdBLHk0qwva-JW4W4wQ_1_2"></a><a id="Tc_S9HI9lFVhkWKnvWkdd_eSQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:1.99%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Symbol(s)</b></p></td><td style="vertical-align:bottom;width:1.99%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:39.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:Security12bTitle" id="Tc_CxWM6G0Wk0GcELrLjr6wDQ_2_0">Class A Common Stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" name="dei:TradingSymbol" id="Tc_ZTjGdTDWrkadmaAOIT-BaA_2_2">HSDT</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_ZISKHaD7NU-w6377aTgyEQ_2_4">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">Emerging growth company&#160;<ix:nonNumeric contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_3pmh4hOSfkyCpI9Nr2S00Q"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_9ee04fb7_ed83_4564_acb9_d8bd1c211a46"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 5.02</b></span><b style="font-weight:bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On September 24, 2025, Helius Medical Technologies, Inc. (the &#8220;Company&#8221;) entered into side letter agreements with Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer, Treasurer and Secretary (together, the &#8220;Side Letters&#8221;). The Side Letters provide for one-time discretionary cash bonuses paid to Mr. Andreeff and Mr. Mathiesen in amounts equal to $890,000 and $610,000, respectively (together, the &#8220;Cash Bonuses&#8221;). The Cash Bonuses will directly offset any severance, bonus opportunity, equity, retirement or other benefit under any plan or arrangement of the Company to which Mr. Andreeff and Mr. Mathiesen would otherwise be entitled. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In consideration of the payment of the Cash Bonuses, each of Mr. Andreeff and Mr. Mathiesen have agreed that the offerings consummated on September 18, 2025, as previously disclosed in the Company&#8217;s Current Report on Form 8-K filed on September 18, 2025, do not constitute a Change in Control (as defined Mr. Andreeff&#8217;s and Mr. Mathiesen&#8217;s employment agreements, as applicable (together, the &#8220;Employment Agreements&#8221;) or give rise to an event constituting Good Reason under the Employment Agreements. To the extent any amounts become due or claimed to be due to Mr. Andreeff or Mr. Mathiesen under the Employment Agreements or otherwise upon or following any termination of Mr. Andreeff&#8217;s or Mr. Mathiesen&#8217;s employment with the Company, including without limitation any severance, change-in-control severance, pro&#8209;rata bonus, continued COBRA subsidies, or other cash amounts, such amount will be offset dollar-for-dollar against the Cash Bonuses, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The foregoing description of the Side Letters does not purport to be complete and is qualified in its entirety by the terms and conditions of the Side Letters, which are attached hereto as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K (this &#8220;Report&#8221;) and are incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_7e1a5a8a_847a_4496_badf_06f3680b2872"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 7.01</b></span><b style="font-weight:bold;">Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On September 25, 2025, the Company issued a press release announced the filing of its U.S. Food and Drug Administration (&#8220;FDA&#8221;) 510(k) submission for the Portable Neuromodulation Stimulator device label expansion seeking an indication for gait and balance deficit in patients with chronic stroke symptoms. The submission was made with data generated in the Company&#8217;s Stroke Registrational Program and was filed under its current FDA Breakthrough Device Designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A copy of the press release is furnished as Exhibit 99.1 to this Report and incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">filing. The Company&#8217;s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_5befe1f3_8669_4d77_8762_9d133847e326"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:58.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Item 9.01</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (d) Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:87.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit No. </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Description </p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hsdt-20250924xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Side Letter, dated as of September 24,2025, between the Company and Dane C. Andreeff</span></a>.</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hsdt-20250924xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Side Letter, dated as of September 24,2025, between the Company and Jeffrey S. Mathiesen</span></a>.</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hsdt-20250924xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated September 25, 2025</span></a>.</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within Inline XBRL document).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_df5f9a28_1efd_40a4_9895_7d95df7f3fdf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">SIGNATURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:44.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:44.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.09%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HELIUS MEDICAL TECHNOLOGIES, INC.</b></p></td></tr><tr><td style="vertical-align:middle;width:44.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: September 25, 2025</p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.96%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/&#160;Jeffrey S. Mathiesen</p></td></tr><tr><td style="vertical-align:bottom;width:44.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Jeffrey S. Mathiesen</p></td></tr><tr><td style="vertical-align:bottom;width:44.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer, Treasurer and Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>hsdt-20250924xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 9/24/2025 09:30:32 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.14%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:11pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:11pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:11pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="position:relative;vertical-align:top;width:50.14%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:16.5pt;width:0pt;"></div><div style="clear:left;float:left;height:49.51pt;margin-left:5.25pt;margin-right:9pt;width:110.14pt;z-index:251658240;"><div style="height:49.36pt;left:0pt;padding-bottom:0.15pt;position:relative;width:110.14pt;"><img src="hsdt-20250924xex10d1002.jpg" alt="Graphic" style="height:49.36pt;width:110.14pt;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:11pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">642 Newtown Yardley Road, Suite 100</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Newtown, PA 18940</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">215.944.6100</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:11pt;text-align:right;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">https://heliusmedical.com/</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;">September 24, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-style:italic;font-weight:bold;">Personal and Confidential</font></p><p style="font-family:'Cambria';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dane C. Andreeff </font></p><p style="font-family:'Cambria';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">140 East St. Lucia Lane</font></p><p style="font-family:'Cambria';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Santa Rosa Beach, Florida 32459</font></p><p style="font-family:'Cambria';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Re:</font></font><font style="font-style:italic;font-weight:bold;">Project Sumtera</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Dear Mr. Andreeff:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">This Letter Agreement (this <font style="font-style:italic;font-weight:bold;">&#8220;Letter Agreement&#8221;</font>) is entered into by and between Helius Medical Technologies, Inc., a Delaware corporation (the <font style="font-style:italic;font-weight:bold;">&#8220;Company&#8221;</font>) and you, Dane Andreeff (the <font style="font-style:italic;font-weight:bold;">&#8220;Executive&#8221;</font>), effective as of September 24, 2025. Reference is made to that certain Employment Agreement dated June 14, 2021 entered into by and between the Company and the Executive (as amended, the <font style="font-style:italic;font-weight:bold;">&#8220;Employment Agreement&#8221;</font>). &#160;Capitalized terms used but not defined in this Letter Agreement have the meanings given in the Employment Agreement.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Transaction Bonus.</b><font style="font-size:10pt;"> In consideration of the agreements in this Letter Agreement, the Company hereby agrees to pay you a one-time discretionary cash bonus in the gross amount of $890,000.00 (the </font><font style="font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Bonus&#8221;</font><font style="font-size:10pt;">), less required withholdings, payable on within 6 business days following the closing of the Transaction, provided you remain employed by the Company through such payment date (unless otherwise agreed in writing). The Bonus is a special, discretionary payment, will directly offset any severance, bonus opportunity, equity, retirement or other benefit under any plan or arrangement of the Company unless required by law, and is not intended to create any ongoing or recurring entitlement. &#160;For purposes of this Letter Agreement,</font><font style="font-size:10pt;font-style:italic;font-weight:bold;"> &#8220;Transaction&#8221;</font><font style="font-size:10pt;"> means the transaction whereby the Company entered into those certain securities purchase agreements dated September 15, 2025 with certain accredited investors pursuant to which the Company agreed to sell and issue to such investors in a private placement (i) shares of the Company&#8217;s common stock; (ii) pre-funded warrants to purchase shares of common stock and (iii) stapled warrants to purchase shares of common stock, together with any related agreements, transactions or understandings entered into by the Company ancillary thereto.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Waiver; No Change in Control or Good Reason.</b><font style="font-size:10pt;"> In consideration of the payment of the Bonus and the agreements set forth in this Letter Agreement, the Executive acknowledges and agrees that the Transaction and any actions taken in connection therewith (including changes as they may relate to the Executive in reporting lines, organizational structure or equity terms related to the Transaction) do not, and will not, constitute a Change in Control or give rise to an event constituting Good Reason under the Employment Agreement. &#160; In addition, upon receipt of the Bonus, the Executive irrevocably waives and releases any right to assert that the Transaction constitutes a Change in Control. &#160;For the avoidance of doubt, this waiver is limited to the Transaction and actions reasonably related thereto and does not waive Good Reason rights arising from events unrelated to the Transaction that occur after the closing date of the Transaction, subject to the Employment Agreement&#8217;s notice and cure provisions.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Offset; Credit; Repayment.</b><font style="font-size:10pt;"> Both the Company and the Executive hereby agree that the Bonus will be offset dollar-for-dollar against, and the Company may set off or recoup the Bonus from, any and all amounts that may become due or claimed to be due to the Executive under the Employment Agreement or otherwise upon or following any termination of the Executive&#8217;s employment with the Company, including without limitation any severance, change-in-control severance, pro</font><font style="font-size:10pt;">&#8209;</font><font style="font-size:10pt;">rata bonus, continued COBRA subsidies, or other cash amounts (collectively, the </font><font style="font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Termination Amounts&#8221;</font><font style="font-size:10pt;">). &#160;If and to the extent any setoff or recoupment described above is not permitted by applicable law or would result in noncompliance with Section 409A of the Internal Revenue Code (</font><font style="font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Section 409A&#8221;</font><font style="font-size:10pt;">), the Executive agrees to promptly repay to the Company, upon written demand and in no event later than thirty (30) days thereafter, an amount equal to the lesser of (i) the Bonus (net of taxes previously withheld) and (ii) the aggregate cash value of the Termination Amounts (net of taxes withheld) actually paid to the Executive, until the Bonus has been fully recovered. The parties will cooperate in good faith to implement any lawful alternative that </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:8.8pt;"><td style="vertical-align:top;width:49.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Cambria';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dane C. Andreeff</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">September 24, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Page 2</p></td><td style="vertical-align:top;width:50.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><b style="color:#ff0000;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"><img src="hsdt-20250924xex10d1001.jpg" alt="Graphic" style="display:inline-block;height:27.85pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:62.14pt;"></b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:10pt;">achieves the economic effect of this Section 3 while complying with applicable law and Section 409A. &#160;Nothing herein permits any deduction from wages where prohibited by law; this </font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</u><font style="font-size:10pt;"> will be applied to non-wage amounts first and otherwise to the maximum extent permitted by law.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Section 409A. </b><font style="font-size:10pt;">This Letter Agreement is intended to be administered and interpreted to comply with, or be exempt from, Section 409A. &#160;Any right of setoff, recoupment, or repayment will be effected only to the extent permitted under Section 409A. &#160;Each payment hereunder is a separate payment for Section 409A purposes.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">5.</font><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">No Other Amendments; Clawback.</b><font style="font-size:10pt;"> &#160;Except as expressly set forth herein, the Employment Agreement and the Executive&#8217;s equity and benefit arrangements remain in full force and effect. This Letter Agreement does not constitute a general release of claims. The Bonus is subject to the Company&#8217;s clawback, recoupment, and compensation recovery policies as in effect from time to time and to applicable law and Nasdaq listing standards. &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">6.</font><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Governing Law; Entire Agreement; Counterparts.</b><font style="font-size:10pt;"> This Letter Agreement will be governed by and construed in accordance with the laws of the State of Delaware, without regard to its conflict of laws rules. &#160;This Letter Agreement, together with the Employment Agreement, constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes any prior discussions on such subject. This Letter Agreement may be executed in counterparts (including by electronic signature or PDF), each of which will be deemed an original and together constitute one agreement.</font></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">In Witness Whereof</b><font style="font-variant:small-caps;">,</font> the Company and the Executive have caused this Letter Agreement have caused their signatures to this Letter Agreement to be duly executed as of the date first written above.</p><div style="margin-left:-4.5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">THE COMPANY:</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">THE EXECUTIVE:</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:6pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Helius Medical Technologies, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:6pt;text-transform:uppercase;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Jeffrey S. Mathiesen</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:95.63pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Name: </font></font>Jeffrey S. Mathiesen</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Title:   </font></font>Chief Financial Officer, Treasurer and Secretary</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:6pt;text-transform:uppercase;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:6pt;text-transform:uppercase;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Dane Andreeff</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:135.36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Dane Andreeff </b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>hsdt-20250924xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 9/24/2025 09:30:33 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.14%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:11pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:11pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:11pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="position:relative;vertical-align:top;width:50.14%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="clear:both;"></div><div style="clear:left;float:left;height:14.25pt;width:0pt;"></div><div style="clear:left;float:left;height:49.51pt;margin-left:5.25pt;margin-right:9pt;width:110.14pt;z-index:251658240;"><div style="height:49.36pt;left:0pt;padding-bottom:0.15pt;position:relative;width:110.14pt;"><img src="hsdt-20250924xex10d2002.jpg" alt="Graphic" style="height:49.36pt;width:110.14pt;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:11pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">642 Newtown Yardley Road, Suite 100</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Newtown, PA 18940</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">215.944.6100</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:11pt;text-align:right;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">https://heliusmedical.com/</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-size:12pt;"><a name="_Hlk209526513"></a></font>September 24, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-style:italic;font-weight:bold;">Personal and Confidential</font></p><p style="font-family:'Cambria';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Jeffrey S. Mathiesen</font></p><p style="font-family:'Cambria';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">12784 Kinross Lane</font></p><p style="font-family:'Cambria';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Naples, Florida 34120</font></p><p style="font-family:'Cambria';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Re: </font></font><font style="font-style:italic;font-weight:bold;">Project Sumtera</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;">Dear Mr. Mathiesen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">This Letter Agreement (this <font style="font-style:italic;font-weight:bold;">&#8220;Letter Agreement&#8221;</font>) is entered into by and between Helius Medical Technologies, Inc., a Delaware corporation (the <font style="font-style:italic;font-weight:bold;">&#8220;Company&#8221;</font>) and you, Jeffrey S. Mathiesen (the <font style="font-style:italic;font-weight:bold;">&#8220;Executive&#8221;</font>), effective as of September 24, 2025. &#160;Reference is made to that certain Employment Agreement dated June 14, 2021 entered into by and between the Company and the Executive (as amended, the <font style="font-style:italic;font-weight:bold;">&#8220;Employment Agreement&#8221;</font>). &#160;Capitalized terms used but not defined in this Letter Agreement have the meanings given in the Employment Agreement.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><a name="_Hlk209526456"></a><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Transaction Bonus.</b><font style="font-size:10pt;"> In consideration of the agreements in this Letter Agreement, the Company hereby agrees to pay you a one-time discretionary cash bonus in the gross amount of $610,000.00 (the </font><font style="font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Bonus&#8221;</font><font style="font-size:10pt;">), less required withholdings, payable on within 6 business days following the closing of the Transaction, provided you remain employed by the Company through such payment date (unless otherwise agreed in writing). The Bonus is a special, discretionary payment, will directly offset any severance, bonus opportunity, equity, retirement or other benefit under any plan or arrangement of the Company unless required by law, and is not intended to create any ongoing or recurring entitlement. &#160;For purposes of this Letter Agreement,</font><font style="font-size:10pt;font-style:italic;font-weight:bold;"> &#8220;Transaction&#8221;</font><font style="font-size:10pt;"> means the transaction whereby the Company entered into those certain securities purchase agreements dated September 15, 2025 with certain accredited investors pursuant to which the Company agreed to sell and issue to such investors in a private placement (i) shares of the Company&#8217;s common stock; (ii) pre-funded warrants to purchase shares of common stock and (iii) stapled warrants to purchase shares of common stock, together with any related agreements, transactions or understandings entered into by the Company ancillary thereto.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Waiver; No Change in Control or Good Reason.</b><font style="font-size:10pt;"> In consideration of the payment of the Bonus and the agreements set forth in this Letter Agreement, the Executive acknowledges and agrees that the Transaction and any actions taken in connection therewith (including changes as they may relate to the Executive in reporting lines, organizational structure or equity terms related to the Transaction) do not, and will not, constitute a Change in Control or give rise to an event constituting Good Reason under the Employment Agreement. &#160; In addition, upon receipt of the Bonus, the Executive irrevocably waives and releases any right to assert that the Transaction constitutes a Change in Control. &#160;For the avoidance of doubt, this waiver is limited to the Transaction and actions reasonably related thereto and does not waive Good Reason rights arising from events unrelated to the Transaction that occur after the closing date of the Transaction, subject to the Employment Agreement&#8217;s notice and cure provisions.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Offset; Credit; Repayment.</b><font style="font-size:10pt;"> Both the Company and the Executive hereby agree that the Bonus will be offset dollar-for-dollar against, and the Company may set off or recoup the Bonus from, any and all amounts that may become due or claimed to be due to the Executive under the Employment Agreement or otherwise upon or following any termination of the Executive&#8217;s employment with the Company, including without limitation any severance, change-in-control severance, pro</font><font style="font-size:10pt;">&#8209;</font><font style="font-size:10pt;">rata bonus, continued COBRA subsidies, or other cash amounts (collectively, the </font><font style="font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Termination Amounts&#8221;</font><font style="font-size:10pt;">). &#160;If and to the extent any setoff or recoupment described above is not permitted by applicable law or would result in noncompliance with Section 409A of the Internal Revenue Code (</font><font style="font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Section 409A&#8221;</font><font style="font-size:10pt;">), the Executive agrees to promptly repay to the Company, upon written demand and in no event later than thirty (30) days thereafter, an amount equal to the lesser of (i) the Bonus (net of taxes previously withheld) and (ii) the aggregate cash value of the Termination Amounts (net of taxes withheld) actually paid to the Executive, until </font></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:8.8pt;"><td style="vertical-align:top;width:49.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Cambria';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Jeffrey S. Mathiesen</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">September 24, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Page 2</p></td><td style="vertical-align:top;width:50.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><b style="color:#ff0000;font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"><img src="hsdt-20250924xex10d2001.jpg" alt="Graphic" style="display:inline-block;height:27.85pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:62.14pt;"></b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:10pt;">the Bonus has been fully recovered. The parties will cooperate in good faith to implement any lawful alternative that achieves the economic effect of this Section 3 while complying with applicable law and Section 409A. &#160;Nothing herein permits any deduction from wages where prohibited by law; this </font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</u><font style="font-size:10pt;"> will be applied to non-wage amounts first and otherwise to the maximum extent permitted by law.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Section 409A. </b><font style="font-size:10pt;">This Letter Agreement is intended to be administered and interpreted to comply with, or be exempt from, Section 409A. &#160;Any right of setoff, recoupment, or repayment will be effected only to the extent permitted under Section 409A. &#160;Each payment hereunder is a separate payment for Section 409A purposes.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">5.</font><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">No Other Amendments; Clawback.</b><font style="font-size:10pt;"> &#160;Except as expressly set forth herein, the Employment Agreement and the Executive&#8217;s equity and benefit arrangements remain in full force and effect. This Letter Agreement does not constitute a general release of claims. The Bonus is subject to the Company&#8217;s clawback, recoupment, and compensation recovery policies as in effect from time to time and to applicable law and Nasdaq listing standards. &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">6.</font><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Governing Law; Entire Agreement; Counterparts.</b><font style="font-size:10pt;"> This Letter Agreement will be governed by and construed in accordance with the laws of the State of Delaware, without regard to its conflict of laws rules. &#160;This Letter Agreement, together with the Employment Agreement, constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes any prior discussions on such subject. This Letter Agreement may be executed in counterparts (including by electronic signature or PDF), each of which will be deemed an original and together constitute one agreement.</font></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">In Witness Whereof</b><font style="font-variant:small-caps;">,</font> the Company and the Executive have caused this Letter Agreement have caused their signatures to this Letter Agreement to be duly executed as of the date first written above.</p><div style="margin-left:-4.5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><a name="_iDocIDField_EOD"></a><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">THE COMPANY:</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">THE EXECUTIVE:</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:6pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Helius Medical Technologies, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:6pt;text-transform:uppercase;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Dane C. Andreeff</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:106.75pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Name: </font></font>Dane C. Andreeff</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Title:   </font></font>President and Chief Executive Officer</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:6pt;text-transform:uppercase;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:6pt;text-transform:uppercase;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Jeffrey S. Mathiesen</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:112.58pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Jeffrey S. Mathiesen </b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>hsdt-20250924xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 9/24/2025 09:30:32 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Helius Announces FDA 510(k) Submission for PoNS&#174; Device Label Expansion in Stroke </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device Designation</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">NEWTOWN, Pa., Sept 25, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), today announced the filing of its U.S. Food and Drug Administration (FDA) 510(k) submission for the PoNS (Portable Neuromodulation Stimulator) device label expansion seeking an indication for gait and balance  deficit in patients with chronic stroke symptoms. The submission was made with data generated in its Stroke Registrational Program (SRP) and was filed under its current FDA Breakthrough Device Designation.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">All statistical analyses for the Functional Gait Assessment (FGA) primary endpoint demonstrated PoNS superior effectiveness in improving gait deficit by achieving a clinically meaningful mean improvement of more than 5 points, which was statistically significant across all studies (p&lt;0.05) and was maintained for at least 12 weeks after completion of the therapy. Conversely the control group achieved, across all trials, a mean FGA improvement of less than 4 points, which fell below the 4.2-point Minimal Detectable Change (MDC) that reflects clinical meaningfulness of the therapeutic intervention. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;Substantial evidence across the SRP trials supports the superiority of active PoNS Therapy&#174; as compared to physical therapy alone, when applied in standard clinical settings for stroke rehabilitation,&#8221; said Antonella Favit-Van Pelt, M.D., Ph.D., Helius&#8217; Chief Medical Officer. &#8220;The totality of data in stroke survivors with gait deficits confirms the broader evidence of PoNS therapeutic effect in improving walking disability by enhancing and potentiating the benefit of physical therapy. Consistent with the existing body of clinical evidence, PoNS also confirms to be a safe and well tolerated therapy.&#8221; </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">PoNS efficacy and safety was clinically established from three clinical trials across 10 sites and 159 enrolled chronic stroke survivors with gait deficit due to stroke. The studies were structured to assess the effectiveness and safety of the PoNS device in conjunction with routine physical rehabilitation therapy over a 12-week treatment period. Participants were also followed for 12 weeks after completion of treatment to assess durability of treatment effect. Primary efficacy endpoints for gait (by FGA) and balance (by the Berg Balance Score), as well as key secondary endpoints including risk of falling (determined by FGA &lt;23) and durability of effect (established at &lt;30% reduction of FGA improvement 12 week after completion of study treatment) were analyzed, across the two pivotal studies, using a propensity score design methodology adjusted for multiplicity control.  Study success was achieved by demonstrating superiority, using the Hochberg method, for either primary endpoint, which, then, allowed for analysis of the key secondary endpoints with the same methodology.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">Overall, the primary endpoint was met and statistically significant for the FGA primary endpoint. In the primary analysis of the pooled pivotal randomized controlled and single-arm studies, treatment with active PoNS plus physical therapy (PT) led to an adjusted mean change in FGA of 5.37 points (95% CI: 4.23 to 6.52) at Week 12 as compared to a change of 3.31 points (95% CI 1.96 to 4.76) in the control group (sham PoNS plus PT). The treatment group difference by propensity adjustment was 2.06 (95% CI 0.29 to 3.84) with a 2-sided p-value of 0.0233 that met the Hochberg requirement for multiplicity (&lt; 0.025) and, therefore, demonstrated statistical superiority.  Durability of active PoNS therapeutic effect achieved at Week 12 was also demonstrated, with a mean percentage reduction in FGA ranging between -</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">4.71% and -4.97% and with 89.7% (95% CI 81.8% to 97.5%) of subjects meeting the durability performance goal. Improvement from baseline to Week 12 was also demonstrated for BBS in the active PoNS group although it did not reach statistically significant between-group separation. Similarly, risk of falling was resolved in 17.4% of subjects in the active PoNS group as compared to 8.9% in the control subjects, albeit not statistically significant. Treatment with PoNS was confirmed to be safe and well-tolerated with no incidence of treatment-related SAEs, across the SRP trials and existing RWE data, and adverse events (ranging between 0.0% and 14.8%) that were unrelated to the PoNS device.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&quot;Submitting our 510(k) application to the FDA brings the benefits on gait from PoNS Therapy one step closer to stroke patients,&quot; said Dane Andreeff, CEO of Helius. &quot;I&#39;m incredibly proud of our team and thankful to the clinicians who facilitated this trial as we work together to increase patient access to this powerful therapy. We&#8217;re optimistic about a positive FDA outcome and the opportunity to support those living with the effects of stroke.&quot;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">About the PoNS Device and PoNS Therapy</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Portable Neuromodulation Stimulator (&#8220;PoNS&#8221;) is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it&#8217;s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (&#8220;mmTBI&#8221;) and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com.  </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">About Helius Medical Technologies, Inc. </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain&#8217;s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company&#8217;s first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS or Helius Medical Technologies, visit www.heliusmedical.com.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Company has adopted a digital asset treasury strategy focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises that produce consistent on-chain yield generation. Helius will provide access to the Solana network.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Cautionary Disclaimer Statement </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;continue,&#8221; &#8220;will,&#8221; &#8220;goal,&#8221; &#8220;aim&#8221; and similar expressions. Such forward-looking statements include, among others, statements regarding future presentation and uses of the SRP study results, successful outcome of the FDA submission, the availability of commercial reimbursement and the uses and effectiveness of PoNS and PoNS Therapy. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company&#8217;s expectations include uncertainties associated with the Company&#8217;s capital requirements to achieve its business objectives, availability of funds, the Company&#8217;s ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company&#8217;s ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company&#8217;s ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the &#8220;Risk Factors&#8221; section of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at </font><font style="font-family:'Times New Roman','Times','serif';">www.sec.gov</font><font style="font-family:'Times New Roman','Times','serif';"> or </font><font style="font-family:'Times New Roman','Times','serif';">www.sedar.com</font><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Investor Relations Contact </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Philip Trip Taylor</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Gilmartin Group</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">investorrelations@heliusmedical.com</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.38;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Pantera Capital Management LP</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">ir@panteracapital.com</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">press@panteracapital.com</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>hsdt-20250924x8k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hsdt-20250924x8k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !H . # 2(  A$! Q$!_\0
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MRNW_ (F?/\3TH4<TJ4Z:M%*-DO\ "@HHHKZ4^5"BBB@ HHHH **** "BBB@
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M_P SE_UZQ?\ L]?GS>_\?EQ_UU?_ -"->]A/^15AO^W_ /THZ<#_ ,C?'?\
M</\ ])9#7W5_P3=_Y%[QS_U]VO\ Z ]?"M?=7_!-W_D7O'/_ %]VO_H#UZN5
M?[W'Y_D8<5_\BBK_ -N_^E(^RZ^/_P#@H7_R#/!?_7>Y_P#0%K[ KX__ ."A
M?_(,\%_]=[G_ - 6OOX[GX"]CGO^"?(SXK\7?]>4'_HPU]P8'H*^(/\ @GS_
M ,C7XN_Z\H/_ $8:^X*);BCL<S\2P/\ A7OB3C_F'S_^BS7YC_ S_DK7@O\
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M "L2,84>M>HUQU_\6/#NG^+=1\-R7,CZKI^G-JES%'$66.%2!RW3=R#MZXK
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M4,,A,C87=Y9;GK]ZM6R\81>#/'8M/AUJ^I7\FH:FQU#P3J6GR?Z/N)\R='8
,QJ3SDDJ:**+ ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>hsdt-20250924xex10d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hsdt-20250924xex10d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  [ ((# 2(  A$! Q$!_\0
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M'RU%.G>+W^..W=?TSXW'45^NOP0_Y(_X._[!5O\ ^BQ7Y%#J*_77X(?\D?\
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M,H_>'^#&?TK=^%7P[U'Q5^R1/X8EMI;#4KF.X$<5U&T3!Q*60$, 0"0!GWH
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M;G>0&C\G[NP?*/P%*PKGT;XF\<6GA?1[74IK.^O+:X9%7['#YC MC;D9&,Y
MK-/Q9TA&U,2VNH0II[".9F@'^M) $2@,26)(&,8]ZX30]<OO$WP2TF[U*?[3
M<?;K=-^Q4^59% &% %<5KVHS1^+_ (FVZ")%MR;R-UA02+*CH5;?C<0#V)Q[
M4#/=9?BEHUIE+Y+O3;D112FUNXMDH$DGEJ-N>3N],\<U63XS>&7MIY5N)V\D
MS(Z"!B^^-U0IMZEBSIM'?->/:;=OXST^76-;2'4-3%E8,MS+"FY#]N(RN -O
M'IBLO4K*&WN[RYB3RYAH5Y=;U)'[V*]!C?ZC:/R /%%@/H30_B1I&NWD-DBW
M5I>OYP>VNX3&\)BV;@_.!Q(A&"00:SH/C-X?F@FFVW\8\M);59+1@U\CR"-&
M@'\>YB .A^8'H<UX)IGBK5$'@[6Q=9U/5M2O8;V=HU;SD+P(5VD8 VJ!P!TJ
M'1]3NKOP_P"+[F:=GG\+P6\6CN>MHJ79*@?WON)RV20,'(IV"Y]$:G\5M*TB
M%3>6FHP7+102?8WMP)1YLQA13\V,EU/?&.<U>TGQ]8ZSXA;1K>UO?M<4$<TY
M>(;+?>NY5<@\,1Z9';.>*^8+ZZ9/ +WH2$S>3:S;6A0Q[O[8F/\ JR-F,_PX
MQ[5VG@O7[W7OC+X52\:)Q!IZO&T5O'$R[K4DKN10=F3G9G;G!QP*+!<^DJ*0
&=**D9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>hsdt-20250924xex10d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hsdt-20250924xex10d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !C -T# 2(  A$! Q$!_\0
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M+_V#[;^35]U'<_$6?5W[*-U/>_ GPW-<323S,)]TDK%F/[Y^I->NUX[^R/\
M\D"\,_2?_P!'/7L5)[C/E+]O75K[2M(\'&RO;BS+SW(8V\K)NPL>,X/-2_L&
MZM?:KX=\6->WEQ>,EU %-Q*SE?D;ID\50_X*"?\ (&\%_P#7Q=?^@QU+_P $
M_O\ D6_%_P#U]P?^@-5=!=3ZRHKF?B#\0]$^&7AV;6=<NA;VJ?*JCEY6[*H[
MDU\G>)?V^-7EOG&A>'K6&T!^5KYV=V'J0N /S-2E<#[7HKXR\'?M[7?V](O$
MV@1?9&8!I]/<[D'KL;K^=?6_A?Q1IGC/0K75](NDO+"Y7='*A_,'T(]*&K#/
MC+]OS_D>O#/_ &#7_P#1K5ZU^PU_R1N?_L)S?^@I7DO[?G_(]>&?^P:__HUJ
M]:_8:_Y(W/\ ]A.;_P!!2J>PD>)?M ? ?QYXJ^+_ (DU72O#=W>6%S.K13QJ
M-KC8HR.?:OL?X1:3=Z%\,/"VG7\#6M[:Z=#%-"_5'"@$&O /BW^V+J_PZ^(>
ML^';?0+2[AL91&LTDS*S94'D8]Z^B? _BJ7Q7X T?Q!+"L$U]8I=M"IR%++N
MP#2>P'2T5\;Z+^W)K>I^)['2V\-V:)<7:6Q<3MD!G"YZ>]?9%)JPPHKQW]I#
MXX7OP1TC1;RRTZ'46OIY(F6:0H%"J#D8'O6;^S=^T)J'QONM;BO=*@TX6"1,
MIAD+[MQ(YR/:BP'NE%<;\4?BMH7PD\.MJNMSE0QV06T?,D[_ -U1_,]!7RMK
M7[?&MS7KG2O#=G!:@_*+J5G<CWQ@"A*XKGVW17R1X%_;RM+R[CM_%.AFPC8X
M-W9.9%7W*GG'TS7U7I&JVNNZ7:ZC8S"XL[J)9H95Z,K#(-#5AGYP4445_+)_
M6I[I\-O^39?BU_UX7?\ Z2&O@BOO?X;?\FR_%K_KPN__ $D-?!%?J%+_ )%^
M%_PO_P!*9\CEG^^XW_&O_24%?IO^Q)_R;IX>_P"N]W_Z425^9%?IO^Q)_P F
MZ>'O^N]W_P"E$E>[DG^\O_"_S1XO&G_(MC_C7Y2/=Z_/3]MO_DN$O_8/MOY-
M7Z%U^>G[;?\ R7"7_L'VW\FK[J.Y^(LW/@_^V#;_  O^'VE^&W\.R7S6?F9G
M6X"AMSLW3'O79_\ #P&U_P"A1F_\"A_A6-\$/V2O#7Q+^&>D>(K_ %+4(+N\
M$F^.$KL&V1E&,^PKN_\ A@_P?_T%]4_-/\*>@:GS]^T1^T3#\<K+1((M'?2S
MITDKDO*'W[PH].,;:]I_X)_?\BWXO_Z^X/\ T!J\H_:>_9_T7X*V'A^?2;V[
MNFU"69)!<[<*$"$8Q_O&O5_^"?W_ "+?B_\ Z^X/_0&H>PNIX_\ M@?$FX\:
M?%2[TF.8G2]$/V6*,'Y3)_RT?ZYX_"O<OV<OV6?#D'@K3]=\5:<NJ:IJ,0G6
MWG)\N"-N5&.[$8)^M?&GC:[DN_&VN7$XWROJ$[N&[GS#Q7OEE^VSXXLK2&W3
MP_I_EQ($3$4@P ,#O3Z: =7^U;^S3HF@>%)?%OA6S_L\V;+]LLXB3&T9.-Z@
M]"#C/M65^PC\0KBU\1:KX/N)6:TNH3>6R,>$D7&\#Z@Y_"N:\6_M?>,?&/AG
M4]$O- L1:W\#02%8Y,@,,9'O7-_LG+=67QX\-GRI$5S+&Q*D#!B;_"ETU [_
M /;\_P"1Z\,_]@U__1K5ZU^PU_R1N?\ ["<W_H*5Y+^WY_R//AC_ +!K_P#H
MUJ]:_8:_Y(W/_P!A.;_T%*'L-'RI^U#_ ,EW\6_]?"_^BUK[S^#?_)#_  K_
M -@:'_T77P9^U#_R7?Q;_P!?"_\ HM:^\_@W_P D/\*_]@:'_P!%TGL"W/S=
M\(_\E%T;_L*0_P#HT5^L0K\G?"/_ "471O\ L*0_^C17ZQ"G($?*7_!0#_D5
M?"7_ %^S?^BQ6!_P3]_Y"/C#_KE;_P VK?\ ^"@'_(J^$O\ K]F_]%BL#_@G
M[_R$?&'_ %RM_P";4N@=3E/VZ]4N[GXL6%E*[?9+;3(WA3L"[ON/UX'Y5[%^
MRI\,_ &N?"?3[YM.L=8U>;?]O>Y4.\;[B-F#]T 8QZYK:_:E_9ZF^+VFVNK:
M*R)X@T^,QK$YPMS%G.S/8@Y(^IKXNL+SQW\#/$3R0C4/#U^C;75T(20 ]&!X
M84]T(^T_&7[''@;Q+JEI?6$+Z*4G62>"W.8ID!Y7!^[GU%>Z6EI#86L-M;QK
M#!"@CCC08"J!@ #Z5\G?"/\ ;@AU*ZM],\;6<=F\C!!J=KGRP3QEU/*CW&:^
MLX)X[J".:%UDBD4,CJ<A@>A!J7?J,^;/BS^S%L$VJ>$E) RSZ:QY_P" '^E?
M.-W:36-P\%Q$\,R':R.,$'W%?I+7G/Q0^"6B_$BW>9D6PU8#Y+R->OLX[BOS
M?.>%(5[U\![LOY>C].WY>A^GY'Q?4H6H9A[T>DNJ]>Z_'U/#OAM_R;+\6O\
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M6GU#:W]FQ-NB@([Y_O'H<4FK#/$_V_/^1Z\,_P#8-?\ ]&M7K7[#7_)&Y_\
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MN\8^++SQ5HE]_;(EQBQD;9) HZ+'V('YUXS9>,/C/\.4-@LFN6D:?*(IX6D
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82*2/3A<2%_LRL=IVY]1QFOL&BBI8T?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>hsdt-20250924xex10d2001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hsdt-20250924xex10d2001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  [ ((# 2(  A$! Q$!_\0
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M'RU%.G>+W^..W=?TSXW'45^NOP0_Y(_X._[!5O\ ^BQ7Y%#J*_77X(?\D?\
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M,H_>'^#&?TK=^%7P[U'Q5^R1/X8EMI;#4KF.X$<5U&T3!Q*60$, 0"0!GWH
MU?V)?^2*1?\ 7[/_ .A5Y'\3_P#D^+1_^O[3_P#T6E<_\(OC5XW^ 4-[X0N?
M!MQJ;M<,\5K*DD4L<AX(7"G<IQGC\#3K#P_X\U7]IGP[K_B?0KJWN[O4;6[F
M$%O(T-M&<;4+8(&U< Y/&.><T=1GLO[3OP \1^,?$FF^-_!4_P#Q/K"-$>U$
MHBD;RV+))$QXW#.,$CH,>E8/@']KK7?#&O6_AGXIZ')IMUE8VU(0F%USP'DC
M/!4_WDX]C78?&7XN_$SX8^/!=V7A#^VO ZP*F8 79WZL[.H)B(^Z P*D#/4\
M>,?$OQIK7[6>M>'=&\/^"KK37LYF,U_<DN(E; .YPH"H,9Y.2<8%"\P/NA)%
MD170AE89#+R"/6BJVD6 TG2K*Q5C(MM D(<]6"J!G]**@9;KP+]N#_DWW6/^
MOFU_]'+7OM<_XT\*Z3XRTN'3=:L8]1L&N8I&MYL[&96#+D#J,@<'@]ZY\13=
M6C*FNJL=^7UXX7%TJ\E=1DG]SN?G;^S[^R9K_P 8)8=4U+S-#\+ @F[=?WMR
M.XA4]?\ >/ ]Z_2#PYH-IX6T'3](L0RV=C EO"';<VQ1@9/<\5>@ACMX4CB1
M8XT4*J(,!0.@ ["GGI7-@\%3P<;1U;W9Z.;YUB,WJ)U-(+:*Z?YLX[Q#\5_#
MWAC4-0LK^>:.YL8X99$2(MD2ML3;CJ<]?2JS?&#2?(NIDL=4FB@NQ9 Q6P8R
MR[MNU!NR>?4"O//BIHME?>+=:O)X!)<6\4)C?<1CY).P.#S@\UYM>^([_2[+
MQ<;1XH&L];6:%TMXPX?SNK-MRW_ B:].Q\]<^CV^,'A\Q!H/MEW,XC\NVAMF
M,LC.2 @4X^8%3D'&,58O?BCHNG7DMI=K=V]S#9_;I(GMR"B?W3_M?[-> ZC<
MRZ)X6&L63F'4K:WL;N*X^\1*[ON8@Y!SD\$$4S6)9-2\-7/B6YDDEUJXGDMY
M;G>0&C\G[NP?*/P%*PKGT;XF\<6GA?1[74IK.^O+:X9%7['#YC MC;D9&,Y
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&=**D9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>hsdt-20250924xex10d2002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hsdt-20250924xex10d2002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !C -T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z\@^+?[
M0FE^ UET_2_+U37,8* YB@/JY'4_[(_2O+_BW^TQ=:]YVE^%FDL=//RR7Q^6
M64=]O]T>_7Z5X([M(Q9B68G))/)-?F&=<6*-Z&7N[ZR_R_S^X_5LCX/<[8C,
ME9=(?_)?Y??V/L#]F3Q-J?B[2/$>IZM=O>7DM^N7?H!Y:X '0 >@KVJO ?V/
M_P#D4=<_Z_E_]%K7OU?7Y!.53+*,YN[:>OS9\9Q%"-/-*T(*R35DO1!1117T
M!\X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!^:E%%%?RT?UJ?1'P-\177A'X%_$37+(1M>:;%/>0K*,H72WW $>F17:_ ;
M]JCPU\9K>*RE9-%\2A1OTZ=^)3W,3'[P]NH].]>;?#;_ )-E^+7_ %X7?_I(
M:^#;6ZFL;B.>WE>">-@Z21L592.A!'0U^Q9;CJF#P.%Y=4XNZ_[>9^7ULDP^
M<8K&^TTFI*S_ .W5NNJ/VIHKX:_9]_;BFT_[-H7Q!D:XMQB.+6E&73L!*!U'
M^T.?6OMK2M5L];T^"^L+F*\LYU#Q3PL&5U/<$5]OAL72Q<>:F_EU1^99EE6*
MRNI[/$1TZ-;/T_RW+=%%,:5$.&90?0FNP\<?12*P<9!!'J*6@ HIK.J8W,%S
MZFA75_NL&^AH =1110 4444 %%8VN>,M"\-3QPZMK%CILLB[T2ZN%C++G&0"
M>1FK6C:]IOB*T-UI=_;ZA;!BAEMI1(NX=1D=Z +]%<[J7Q$\+Z/>RV=]X@TR
MTNHCB2&>Z1'4^X)R*V[*]M]1M(;JUF2XMIE#QRQ,&5U/0@CJ* )Z*** "BBB
M@ HHHH **** /S4HHHK^6C^M3W3X;?\ )LOQ:_Z\+O\ ])#7P17WO\-O^39?
MBU_UX7?_ *2&O@BOU"E_R+\+_A?_ *4SY'+/]]QO^-?^DH*_3C]B9BW[.OA[
M)S^^NQ_Y,/7YCU^F_P"Q)_R;IX>_Z[W?_I1)7NY)_O+_ ,+_ #1XO&G_ "+H
M_P"-?E(]WKX"_;/UW4M/^-4L5KJ%W;1?V?;G9#.R+G#=@:^_:_/3]MK_ )+A
M+_V#[;^35]U'<_$6?5W[*-U/>_ GPW-<323S,)]TDK%F/[Y^I->NUX[^R/\
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M?.>%(5[U\![LOY>C].WY>A^GY'Q?4H6H9A[T>DNJ]>Z_'U/#OAM_R;+\6O\
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M6GU#:W]FQ-NB@([Y_O'H<4FK#/$_V_/^1Z\,_P#8-?\ ]&M7K7[#7_)&Y_\
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MN\8^++SQ5HE]_;(EQBQD;9) HZ+'V('YUXS9>,/C/\.4-@LFN6D:?*(IX6D
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82*2/3A<2%_LRL=IVY]1QFOL&BBI8T?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>hsdt-20250924.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/24/2025 9:30:44 PM-->
<!--Modified on: 9/24/2025 9:30:44 PM-->
<xsd:schema targetNamespace="http://www.heliusmedical.com/20250924" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:hsdt="http://www.heliusmedical.com/20250924" xmlns:rxp="http://xbrl.sec.gov/rxp/2024" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="hsdt-20250924_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="hsdt-20250924_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>hsdt-20250924_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/24/2025 9:30:44 PM-->
<!--Modified on: 9/24/2025 9:30:44 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>hsdt-20250924_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/24/2025 9:30:44 PM-->
<!--Modified on: 9/24/2025 9:30:44 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="hsdt-20250924.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638943462442074448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638943462442074448" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638943462442074448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638943462442074448" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638943462442074448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638943462442074448" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638943462442074448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638943462442074448" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638943462442074448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638943462442074448" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638943462442074448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638943462442074448" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638943462442074448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638943462442074448" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638943462442074448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638943462442074448" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638943462442074448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638943462442074448" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638943462442074448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638943462442074448" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638943462442074448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638943462442074448" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638943462442084425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638943462442084425" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638943462442084425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638943462442084425" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638943462442084425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638943462442084425" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638943462442084425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638943462442084425" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638943462442084425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638943462442084425" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638943462442084425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638943462442084425" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638943462442094805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638943462442094805" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638943462442094805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638943462442094805" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638943462442094805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638943462442094805" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638943462442104453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638943462442104453" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638943462442104453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638943462442104453" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638943462442104453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638943462442104453" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 24, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 24,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HELIUS MEDICAL TECHNOLOGIES, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4787690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">642 Newtown Yardley Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newtown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">18940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">944-6100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HSDT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="hsdt-20250924x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>hsdt-20250924.xsd</File>
    <File>hsdt-20250924_lab.xml</File>
    <File>hsdt-20250924_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="hsdt-20250924x8k.htm">hsdt-20250924x8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>hsdt-20250924x8k001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "hsdt-20250924x8k.htm": {
   "nsprefix": "hsdt",
   "nsuri": "http://www.heliusmedical.com/20250924",
   "dts": {
    "schema": {
     "local": [
      "hsdt-20250924.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "hsdt-20250924_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hsdt-20250924_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "hsdt-20250924x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hsdt-20250924x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hsdt-20250924x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.heliusmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001104659-25-093161-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-093161-xbrl.zip
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MG[1YNH_[C)HA<??AZF.V-]M<0L-R^P-02P,$%     @ "$@Y6WTT$S6"!0
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MS*>DY#EQ$:P>RE=F;@THNR-P[>V^<F5>U/,V2M'-"TL?_P502P,$%     @
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M:3LN4U:]U46;7Y-=TV+0/SATDP6PCYU*WI'T2Y'51NSR2/%W=LP2+(#TP *
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MN-G[C-HB/F(7/03L_02XFML-=1:X3M\QXO5J^'C2"'JF( #Y5Z4MJC$\)6N
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MH3[QSA)%&-C#)/\\/7(^Z;CQ( -0*%(F=X.], ON!9:/6@A#"!A^F!Q[8,&
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MT>.,)5F ^P9JAPN#<T7'FJ06[5E360 1_S1R ^]+/%'CXU]5F*7U88)F$6(
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M8=*@GAB:EHL:(R075!%=B]LF_7Y@?,&8]4BVHW9!#_<(U)W9O&\-E.1 V>W
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MDJ=(-1]YCA%C:/'J.:T T\;@@ "%WA-0G53IC^H+ FB7PXL+R%,A4!ZH-TJ
M+OY=3[:/+^:\,Z+P\CO)3 B@(7(V7AY+TNN&T9W(&VCBE$5'L%O/036Z1+\L
M1"Q(PFG.'J(Y'*ZXOIK<2D:O"\WAI6U%G'R9BI?O/MIP(*U>SE'G.R6A]E4%
MH1C4K^O75; <.9UYI+EH>J6>:X2_P8-7P%M _!$$0L@A;_(CN_(XR6E/=*?N
M?-ETAE>9WLU3TOSR\G2)B@I")7F5+GEX*<*H6R8^_DWEQP3TB7SH .S&^XQQ
MC5J"OTT'7-Z0PY6 EJ#K%"]'+E8]B!SYV]!DV-G=N.;YU7P.+,11[4\..9\?
MW$_7X%],-9A?F7S4>B,/DGZP[T&CE&%JWH5@:#'E*92HL^FN]K!%8WGFZ"(N
MMGWB1DT#]F(Z\4<H35.J*-1KFMM"KAS!#1[<0*,.K4?5;.3-'TK\K K<>M51
M:C#!F&M;&G]V3>'W-*I:<3:CJ('Z;7\-U/D;IS/[N@]IW4PCCWYRQ1Z<;-ON
M++)I71.U[B2 \H6]S[BY.WKV,9T[9K6)G)ARVCAHKM<$8>4K\VGM[),O\5+K
M=TH4=Q9D%DP5Z9'DS0[K&TYP_<BQ.Z+^>SENM>>[4L4O/+Q5HU+B$H[XXX.1
MK2@U<J(K3_Y[*/Q3>@ BWT?5)_>(>,(1H:J(S5B4)YHS0JC+\!Z^Q-UO,ZKD
MRXDD[T:'\Q:E?-H:*#O&.V.MXJD)%],W1 .$&M:UO]:LR/IXS2>GTC/Y7C9F
MLX<.U4V4W@X/A9JAX@9K>]?F*PIU9L6NOD.]$2H;_2)/\^6I[TI]$-'F9(DW
M%*UVQQ:Y'QX1:X&M(GJU\4%Q>;R0(=S27/=:[NQ,@OQI+.5(9DCYYYA *>7)
M20VUK[\%LR>O[Z!27+@;2Y?U]1<I9\)*BW-&C%(L'C^2G#DBQ?XV4AYKZT3]
M.6?-'6"F55U2[RIX7E.;>.GAFN5;  .=:OO99%?=5C Y/>9*TL]TF3J?+3&L
M9*F<'JY1-AMKE$S#?$*_#X_;75VIKK.V/^PH-F]:ZZG0Y4&-03B%_ D?IZ,O
M#.RP .'>PLDIJ<#"]X:9/9\/7SX\)C$SC+^RB#,Z/!]AWOFQZ\UC$3^)0EJR
MLP?,=ZLMX/YT^N4. 5N$B_A(6\'G: U&6K0TF7 S\>9?&\;F9>WF%U6I=L>L
M&3^?"G@/O"864F!KL%F85$2*W0@B<#>^J>5%WZF.X/)':?D3'EUS*$E?IA:V
MN6%X_%+R$,G*X&KI=9$3YSQ-+$S@R2V,(ISD[?)>G^V9YDH=1DZ @Z:I8TVJ
MVVR%#?>T$/>;46>Y_@1C/=\Y6\%1GZP$R]-KLT<MEIY_O8&*&L$5$;76XD#*
M$KF^UB=Y:R7N\AKX[A2J.)A627-9'K"Y8YXASU)#6@D.6=G!'GXR\=^1H0XN
MUD537SV9M!L0_@T_*]N4%H5F4_D;\,Z T)Z_D_2*/HW]80418'.[M0N&'#1%
M$+KHA+DKP1<'*S,I(7=F#5;&D2;C:(XX^FFJQAPL;D_$E8KL?+L-J.$: K9[
MTQS63!*X/)?Q==X)T6:5Q6]NEU 3[D=E824UBKX&=,35+5X- (1'JE=FY'%:
M%1%%AR(#?B$&'^%*T1]#B_N*/4I/?)I,?3$U6F<BDZQ>IH[YWZ1[NV-6:,VK
M,MJZ168S>22&OWWQ#J7]BSUI!V' =T3 SX*29Q,AMUR(F[21SU.N$[\86LT"
M5%:")[N%LV^M]AY96R!B?OAJXOH'A/BHMI?)E^+A13[WCZY\#/C F<HC"=SR
M/+Y[?%\MTV7'SB/94D-E2?6DC8U]N+]&.]Y'"S)*W2<J=+R!7!/<@\^LBTTG
M"LK&O'H99I+\GE/!3[W\@LZC86..![-:3S[61;;DAZ4=A5&UF:OVWV69KI\7
M"ZLAM\34Z2NF7!&Y%MGM^I&1T3>;"6&0 8^S<[Z%9G)-/,$WG12ABA!I\%.3
M;_ZR:&<J?:"FD.%S:7'1AFH_PB:LFDY6?]4?DO)W.!G>9'G2O:+;?V&Q7F^"
M/WL(6^5@='*77U.VN^A:2^RTEAX]_L)D&T2SWJ!UIS 987'+HH!:O_>$/+7T
M$&=6&N&PBTUIBN"\INUZ1?G!0D!Z_OUK_($JIPS$EUH$!G=GXEKT!@)VF[6'
MKPSO-BO5)177MYQCC_HNJ-RSD#_^U2JUQ&"UM3#9E6LC%/3VCEV;$%0[_QP:
M/- A)E#M%P0&Y:""BX':C=U70Y>J IG#)4SU*2$T+<T)M?RS,-G:.=&\K^6,
MWP$R[? "2:@T^GP3]8&LSS6NIKIGQR85]%K,&V530<,=>I]Y;BB:@V(*E5B-
M?$J8EAS94==<PUT9:.K$2!O%O80]_]RVS*:<?*KJO5M<]S8ZF06(F\K:SO6!
M!V*BN[.?X)$BKO>I,>7<?V9@IOS#5)Y'8 Q_X%0764"[U=PZPKZ1PI/]R3"F
MN>OG[,VL/P=376\!\E&1=A<5U7+;IC7E3U/2XLYDN:[V:O'WP8O=O36C A8K
ME#-F.B$]MD--UJAN0[4N!=X(J[:\8PE$E(A9R#WOO_4S5'R1=K"S[U21MA__
M6'H]>)&M!C67UH7@]<EBGB1C]Y\$^!N;/:CVZ.9ZF[N?%<VY?/;S?G64+64D
MO8 NAJ?"HSR#H_W+]&*7VX?,51<JET1/3L0F*F;W@XQ^$_NSPJK1] AUA(&[
M6=X_-UBVK.\PDJ<$MZVS$*LY(Z^S]5(P[R$YZ.:.D!@\[PQ%LB.*$4FT^LP"
ML%BI]8UWM8<G<Z8\&1-KK22#;^J%J=E"*CJS%LEU[CHNR=.;Q'<_GQ'VJKZD
M\?)<ZU#2UI<,SW+-PT=B_7&W)>.,[VN:ROD=O*3G)!1W7R/;O"OYS$QK0&N'
MW@<^O=W.N)*C7MB*8HW]!U!+ P04    "  (2#E;*?U%&#H1  "C8P  &
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M>CT1/.U<D9)3<:7B:6Y2,]&J[(KW>1R)SL>CX<G1/_;%+\.3J_6N<":1<UC
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MDR]U<%_Y_R;$*_Y/2OP;4$L! A0#%     @ "$@Y6SF:(QB9 P  Y@P  !$
M             ( !     &AS9'0M,C R-3 Y,C0N>'-D4$L! A0#%     @
M"$@Y6WTT$S6"!0  A3X  !4              ( !R ,  &AS9'0M,C R-3 Y
M,C1?;&%B+GAM;%!+ 0(4 Q0    (  A(.5O=()5^L 0  )4H   5
M      "  7T)  !H<V1T+3(P,C4P.3(T7W!R92YX;6Q02P$"% ,4    "  (
M2#E;0^Z,%$<<  "3Q0  %               @ %@#@  :'-D="TR,#(U,#DR
M-'@X:RYH=&U02P$"% ,4    "  (2#E;PPZX)V,9  #Q&@  %P
M    @ '9*@  :'-D="TR,#(U,#DR-'@X:S P,2YJ<&=02P$"% ,4    "  (
M2#E;*?U%&#H1  "C8P  &               @ %Q1   :'-D="TR,#(U,#DR
M-'AE>#$P9#$N:'1M4$L! A0#%     @ "$@Y6SV7^3%@$0  VV0  !@
M         ( !X54  &AS9'0M,C R-3 Y,C1X97@Q,&0R+FAT;5!+ 0(4 Q0
M   (  A(.5NLL\>?NA(  --"   8              "  7=G  !H<V1T+3(P
G,C4P.3(T>&5X.3ED,2YH=&U02P4&      @ "  > @  9WH

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>hsdt-20250924x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hsdt-20250924.xsd" xlink:type="simple"/>
    <context id="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610853</identifier>
        </entity>
        <period>
            <startDate>2025-09-24</startDate>
            <endDate>2025-09-24</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_GB-oXb7IDEG7bdEY56k7gw_2_1">0001610853</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_6HQPzYykZUyxS1BX90dAXA_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Narr_BABod1V0w0S6JdVtIuKTxg">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Narr_mkjTcQIZFUWd2Z7sJxx_vg">2025-09-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Narr_VSVuPOekZkKzyMgTd2V58w">HELIUS MEDICAL TECHNOLOGIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_EbiJOc9j4EibYnRUgUn3Xg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_nOoD7o1cX0eIxeXM4tBBiA_1_1">001-38445</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_ddJzQy76RkyJdNgXi5VGPw_1_2">36-4787690</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Narr_rMwKqncEQ029rA9cB2A4fg">642 Newtown Yardley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Narr_1eWxY3Z1hUe90Rzg1M7oCg">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Narr_tFewQUpYSUuJ9coulBQ1fQ">Newtown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Narr_K7AOauMmyUycdetfxL8uSA">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_fJYV2yo3K0qoPiBnqscbng_4_2">18940</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Narr_gkgkQ9Vda06q7ARU8wSi_Q">215</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Narr_83vQAl32v0W5I9NNdokAzQ">944-6100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_XOGbFb8WaUugQbDK8-Rnew_1_0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_0PsP9epCu0eWsihtncilRA_2_0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_gu_VKPNTZUaCXP7KTQURAw_3_0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_6PjSdbYwqU2Dai-gL1HQOw_4_0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_CxWM6G0Wk0GcELrLjr6wDQ_2_0">Class A Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_ZTjGdTDWrkadmaAOIT-BaA_2_2">HSDT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Tc_ZISKHaD7NU-w6377aTgyEQ_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_9_24_2025_To_9_24_2025_tyYO6o5Vmk6TKsZ2_jmkHA"
      id="Narr_3pmh4hOSfkyCpI9Nr2S00Q">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
